BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 23213092)

  • 41. Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.
    Karivedu V; Jain AL; Eluvathingal TJ; Sidana A
    Curr Urol Rep; 2019 Aug; 20(10):56. PubMed ID: 31468240
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diuretic 18F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique.
    Nayak B; Dogra PN; Naswa N; Kumar R
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):386-93. PubMed ID: 23179944
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma.
    Jadvar H; Kherbache HM; Pinski JK; Conti PS
    Clin Nephrol; 2003 Dec; 60(6):395-400. PubMed ID: 14690256
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cross-modality PET/CT and contrast-enhanced CT imaging for pancreatic cancer.
    Zhang J; Zuo CJ; Jia NY; Wang JH; Hu SP; Yu ZF; Zheng Y; Zhang AY; Feng XY
    World J Gastroenterol; 2015 Mar; 21(10):2988-96. PubMed ID: 25780297
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.
    Suenaga Y; Kitajima K; Ishihara T; Sasaki R; Otsuki N; Nibu K; Minamikawa T; Kiyota N; Sugimura K
    Eur Radiol; 2016 Apr; 26(4):1018-30. PubMed ID: 26188656
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Imaging of acquired cystic disease-associated renal cell carcinoma by contrast-enhanced ultrasonography with perflubutane microbubbles and positron emission tomography-computed tomography.
    Ishikawa I; Morita K; Hayama S; Nakazawa T; Araki I; Higashi K; Miyazawa K; Suzuki K; Nojima T
    Clin Exp Nephrol; 2011 Feb; 15(1):136-40. PubMed ID: 20824295
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
    van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
    J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study.
    Zattoni F; Incerti E; Colicchia M; Castellucci P; Panareo S; Picchio M; Fallanca F; Briganti A; Moschini M; Gallina A; Karnes JR; Lowe V; Fanti S; Schiavina R; Rambaldi I; Ficarra V; Evangelista L
    Abdom Radiol (NY); 2018 Sep; 43(9):2391-2399. PubMed ID: 29302738
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preoperative
    Cho JK; Ow TJ; Lee AY; Smith RV; Schlecht NF; Schiff BA; Tassler AB; Lin J; Moadel RM; Valdivia A; Abraham T; Gulko E; Neimark M; Ustun B; Bello JA; Shifteh K
    Otolaryngol Head Neck Surg; 2017 Sep; 157(3):439-447. PubMed ID: 28608737
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical value of ⁶⁸Ga-DOTATATE-PET/CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET).
    Albanus DR; Apitzsch J; Erdem Z; Erdem O; Verburg FA; Behrendt FF; Mottaghy FM; Heinzel A
    Eur J Radiol; 2015 Oct; 84(10):1866-72. PubMed ID: 26152870
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Three-Dimensional Image Fusion of
    Yu Y; Zhang WB; Liu XJ; Guo CB; Yu GY; Peng X
    J Oral Maxillofac Surg; 2017 Jun; 75(6):1301.e1-1301.e15. PubMed ID: 28320612
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - a multicenter experience.
    Cistaro A; Niccoli Asabella A; Coppolino P; Quartuccio N; Altini C; Cucinotta M; Alongi P; Balma M; Sanfilippo S; Buschiazzo A; Piccardo A; Fanelli M; Sambuceti G; Bomanji J; Baldari S; Bisi G; Fanti S; Rubini G
    Hell J Nucl Med; 2015; 18(2):97-102. PubMed ID: 26187207
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study.
    Hekman MC; Boerman OC; de Weijert M; Bos DL; Oosterwijk E; Langenhuijsen JF; Mulders PF; Rijpkema M
    Clin Cancer Res; 2016 Sep; 22(18):4634-42. PubMed ID: 27103404
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review.
    Roussel E; Capitanio U; Kutikov A; Oosterwijk E; Pedrosa I; Rowe SP; Gorin MA
    Eur Urol; 2022 May; 81(5):476-488. PubMed ID: 35216855
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of N-13 ammonia PET/CT in diagnosing pancreatic necrosis in patients with acute pancreatitis as compared to contrast enhanced CT--results of a pilot study.
    Kashyap R; Mittal BR; Khaliq A; Manrai M; Appasani S; Bhattacharya A; Khandelwal N; Kochhar R
    Pancreatology; 2014; 14(3):154-8. PubMed ID: 24854609
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Renal Masses Detected on FDG PET/CT in Patients With Lymphoma: Imaging Features Differentiating Primary Renal Cell Carcinomas From Renal Lymphomatous Involvement.
    Nicolau C; Sala E; Kumar A; Goldman DA; Schoder H; Hricak H; Vargas HA
    AJR Am J Roentgenol; 2017 Apr; 208(4):849-853. PubMed ID: 28095016
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical role of early dynamic FDG-PET/CT for the evaluation of renal cell carcinoma.
    Nakajima R; Abe K; Kondo T; Tanabe K; Sakai S
    Eur Radiol; 2016 Jun; 26(6):1852-62. PubMed ID: 26403580
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?
    Selzner M; Hany TF; Wildbrett P; McCormack L; Kadry Z; Clavien PA
    Ann Surg; 2004 Dec; 240(6):1027-34; discussion 1035-6. PubMed ID: 15570208
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is a single portal venous phase in contrast-enhanced CT sufficient to detect metastases or recurrence in clear cell renal cell carcinoma? - a single-center retrospective study.
    Hagen F; Peisen F; Spogis J; Mair A; Nikolaou K; Stenzl A; Kruck S; Bedke J; Kaufmann S; Thaiss WM
    Cancer Imaging; 2022 Jan; 22(1):9. PubMed ID: 35063030
    [TBL] [Abstract][Full Text] [Related]  

  • 60. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma.
    Majhail NS; Urbain JL; Albani JM; Kanvinde MH; Rice TW; Novick AC; Mekhail TM; Olencki TE; Elson P; Bukowski RM
    J Clin Oncol; 2003 Nov; 21(21):3995-4000. PubMed ID: 14581422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.